KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Change in Account Payables (2018 - 2025)

Historic Change in Account Payables for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to $21.4 million.

  • Takeda Pharmaceutical's Change in Account Payables fell 8343.19% to $21.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.4 million, marking a year-over-year increase of 10297.35%. This contributed to the annual value of -$46.7 million for FY2025, which is 3189.55% up from last year.
  • According to the latest figures from Q4 2025, Takeda Pharmaceutical's Change in Account Payables is $21.4 million, which was down 8343.19% from $112.2 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Change in Account Payables registered a high of $1.1 billion during Q1 2022, and its lowest value of -$751.0 million during Q2 2022.
  • Moreover, its 5-year median value for Change in Account Payables was $12.0 million (2024), whereas its average is $31.9 million.
  • In the last 5 years, Takeda Pharmaceutical's Change in Account Payables tumbled by 30233.91% in 2022 and then soared by 435276.79% in 2025.
  • Takeda Pharmaceutical's Change in Account Payables (Quarter) stood at $63.7 million in 2021, then crashed by 185.62% to -$54.6 million in 2022, then soared by 970.94% to $475.4 million in 2023, then crashed by 72.84% to $129.1 million in 2024, then crashed by 83.43% to $21.4 million in 2025.
  • Its Change in Account Payables stands at $21.4 million for Q4 2025, versus $112.2 million for Q3 2025 and -$192.0 million for Q2 2025.